SCHEMBL831900

SCHEMBL831900

CS(=O)(=O)NCCc1ccc(S(=O)(=O)NC(=O)c2c(-c3ccc[nH]c3=O)c3cc(Cl)ccc3n2Cc2ccc(F)cc2F)cc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.38
PPARG P37231 2/20 0.36
MAPT P10636 3/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TP53 P04637 5/20 0.34
FLT1 P17948 3/20 0.34
FLT4 P35916 3/20 0.34
KDR P35968 3/20 0.34
BCL2L1 Q07817 1/20 0.33
BAK1 Q16611 1/20 0.33
PTGDR2 Q9Y5Y4 2/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
BCL2 P10415 1/20 0.33
MCL1 Q07820 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831790 0.88 CYP2C8 (0.39) CYP2C8PPARGFLT1FLT4KDR
SCHEMBL832081 0.87 CYP2C8 (0.44) CYP2C8PPARGMEN1KMT2APTGDR2
SCHEMBL831326 0.86 CYP2C8 (0.40) CYP2C8PPARGKMT2AFLT1FLT4
SCHEMBL862901 0.85 CYP2C8 (0.39) CYP2C8PPARGMAPTLMNAMEN1
SCHEMBL862166 0.85 CYP2C8 (0.42) CYP2C8PPARGKMT2AFLT1FLT4
SCHEMBL862560 0.85 FLT1 (0.42) CYP2C8PPARGMEN1KMT2AFLT1
SCHEMBL831558 0.84 CYP2C8 (0.40) CYP2C8PPARGKMT2AFLT1FLT4
SCHEMBL10257280 0.84 CYP2C8 (0.48) CYP2C8PPARGKMT2APTGDR2MCL1
SCHEMBL832498 0.83 CYP2C8 (0.45) CYP2C8PPARGMAPTMEN1KMT2A
SCHEMBL10256531 0.83 FLT1 (0.41) CYP2C8PPARGKMT2AFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885PPARG 4093/4885MAPT 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.